Mutation Information
Mutation Site
|
M552V |
Mutation Type
|
Amino acid level |
Gene/Protein/Region Type
|
P |
Genotype/Subtype
|
D |
Relevant Drug
|
lamivudine (LAM) |
Country
|
Japan |
Literature Information
PubMed PMID
|
11181644
|
Published Year
|
2001 |
Journal
|
The Journal of clinical investigation |
Title
|
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. |
Author
|
Ono SK,Kato N,Shiratori Y,Kato J,Goto T,Schinazi RF,Carrilho FJ,Omata M |
Evidence
|
After receiving lamivudine for 3 years to treatChronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant.
|
|
|